Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886823 | 0.88 | SMYD3 (0.48) | MAPK8CCNE1CDK2LMNASMN1; SMN2 | |
| SCHEMBL5887427 | 0.87 | SMN1; SMN2 (0.46) | MAPK8CCNE1CDK2LMNASMN1; SMN2 | |
| SCHEMBL5887242 | 0.87 | BRD4 (0.47) | CCNE1CDK2HTR2ADRD3SMYD3 | |
| SCHEMBL5887713 | 0.86 | MAPK8 (0.44) | MAPK8LMNASMN1; SMN2TSHRRAB9A | |
| SCHEMBL5887102 | 0.86 | ALDH1A1 (0.40) | MAPK8CCNE1CDK2LMNASMN1; SMN2 | |
| SCHEMBL5887542 | 0.85 | MAPK8 (0.45) | MAPK8CCNE1CDK2HTR2ADRD3 | |
| SCHEMBL5887033 | 0.85 | MAPK8 (0.40) | MAPK8CCNE1CDK2LMNASMN1; SMN2 | |
| SCHEMBL5886718 | 0.85 | CCNE1 (0.45) | MAPK8CCNE1CDK2NPC1RAB9A | |
| SCHEMBL5887109 | 0.85 | MAPT (0.39) | MAPK8CCNE1CDK2LMNASMN1; SMN2 | |
| SCHEMBL5887062 | 0.85 | SMYD3 (0.43) | MAPK8CCNE1CDK2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAPK8 770/4885CCNE1 559/4885CDK2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.